Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis

Reproductive Biology and Endocrinology

Basil Tarlatzis⁴  Samuel Copt³  Pablo Arriagada²  Helen Saunders²  Joan Schertz⁵  Christos A Venetis⁴  Efstratios M Kolibianakis⁴  Philippe Lehert¹ 

[1] Faculty of Medicine, the University of Melbourne, Melbourne 3010, Victoria, Australia;Preglem SA, Chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates, Geneva, Switzerland;Biosensors, rue de Lausanne 31, 1100 Morges, Switzerland;Unit for Human Reproduction, 1st Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki 54124 Thessaloniki, Greece;Fertility Global Clinical Development Unit, EMD Serono, Inc, Rockland, MA 02370, USA (an affiliate of Merck KGaA, Darmstadt, Germany

关键词: Recombinant human luteinizing hormone supplementation;    Recombinant human follicle-stimulating hormone;    Pregnancy;    Poor ovarian response;    In vitro fertilization;   

Others  :  804604
DOI  :  10.1186/1477-7827-12-17

 received in 2013-11-05, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

The potential benefit of adding recombinant human luteinizing hormone (r-hLH) to recombinant human follicle-stimulating hormone (r-hFSH) during ovarian stimulation is a subject of debate, although there is evidence that it may benefit certain subpopulations, e.g. poor responders.

Methods

A systematic review and a meta-analysis were performed. Three databases (MEDLINE, Embase and CENTRAL) were searched (from 1990 to 2011). Prospective, parallel-, comparative-group randomized controlled trials (RCTs) in women aged 18–45 years undergoing in vitro fertilization, intracytoplasmic sperm injection or both, treated with gonadotrophin-releasing hormone analogues and r-hFSH plus r-hLH or r-hFSH alone were included. The co-primary endpoints were number of oocytes retrieved and clinical pregnancy rate. Analyses were conducted for the overall population and for prospectively identified patient subgroups, including patients with poor ovarian response (POR).

Results

In total, 40 RCTs (6443 patients) were included in the analysis. Data on the number of oocytes retrieved were reported in 41 studies and imputed in two studies. Therefore, data were available from 43 studies (r-hFSH plus r-hLH, n = 3113; r-hFSH, n = 3228) in the intention-to-treat (ITT) population (all randomly allocated patients, including imputed data). Overall, no significant difference in the number of oocytes retrieved was found between the r-hFSH plus r-hLH and r-hFSH groups (weighted mean difference −0.03; 95% confidence interval [CI] −0.41 to 0.34). However, in poor responders, significantly more oocytes were retrieved with r-hFSH plus r-hLH versus r-hFSH alone (n = 1077; weighted mean difference +0.75 oocytes; 95% CI 0.14–1.36). Significantly higher clinical pregnancy rates were observed with r-hFSH plus r-hLH versus r-hFSH alone in the overall population analysed in this review (risk ratio [RR] 1.09; 95% CI 1.01–1.18) and in poor responders (n = 1179; RR 1.30; 95% CI 1.01–1.67; ITT population); the observed difference was more pronounced in poor responders.

Conclusions

These data suggest that there is a relative increase in the clinical pregnancy rates of 9% in the overall population and 30% in poor responders. In conclusion, this meta-analysis suggests that the addition of r-hLH to r-hFSH may be beneficial for women with POR.

【 授权许可】

   
2014 Lehert et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hill MJ, Levy G, Levens ED: Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reprod Biomed Online 2012, 24:261-271.
• [2]Fischer R: Understanding the role of LH: myths and facts. Reprod Biomed Online 2007, 15:468-477.
• [3]Sen A, Caiazza F: Oocyte maturation: a story of arrest and release. Front Biosci (Schol Ed) 2013, 5:451-477.
• [4]Shoham Z, Schacter M, Loumaye E, Weissman A, MacNamee M, Insler V: The luteinizing hormone surge–the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995, 64:237-251.
• [5]Sommer L, Zanger K, Dyong T, Dorn C, Luckhaus J, Diedrich K, Klingmuller D: Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol 1994, 131:280-285.
• [6]Doody K, Devroey P, Gordon K, Witjes H, Mannaerts B: LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles. Reprod Biomed Online 2010, 20:565-567.
• [7]UK Summary of product characteristics Luveris 75 IU 2013. [http://www.medicines.org.uk/emc/medicine/8289/spc webcite]
• [8]European Recombinant Human LH Study Group: Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998, 83:1507-1514.
• [9]Howles CM: Luteininzing hormone supplementation in ART. In How to Improve Your ART Success Rates. Edited by Kovacs G. Cambridge, UK: Cambridge University Press; 2011:99-104.
• [10]Ferraretti AP, Gianaroli L, Magli MC, D’Angelo A, Farfalli V, Montanaro N: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004, 82:1521-1526.
• [11]Alviggi C, Mollo A, Clarizia R, De Placido G: Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006, 12:221-233.
• [12]International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonized tripartite guideline: statistical principles for clinical trials E9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf webcite
• [13]Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011. Electronic source is [http://www.cochrane-handbook.org webcite]
• [14]Committee for Proprietary Medicinal Products. Points to consider on application with 1. Meta-analyses 2. One pivotal study CPMP/EWP/2330/99. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003657.pdf]
• [15]Baruffi RL, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, Cavagna M, Oliveira JB, Franco JG Jr: Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online 2007, 14:14-25.
• [16]Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, Tarlatzis BC: Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007, 13:445-452.
• [17]Mochtar MH, van der Veen F, Ziech M, Van Wely M: Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007, 2:CD005070.
• [18]Oliveira J, Mauri A, Petersen CG, Martins AMC, Cornicelli J, Cavanha M, Pontes A, Baruffi R, Franco JG Jr: Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis. J Assist Reprod Genet 2007, 24:67-75.
• [19]Westergaard LW, Bossuyt PMM, van der Veen F, van Wely M: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2003, 1:CD003973.
• [20]Raudenbush S: Analyzing effect sizes: Random effects models. In The handbook of research synthesis and meta-analysis. 2nd edition. Edited by Cooper H, Hedges LV. New York: Russell Sage Foundation; 2012:295-315.
• [21]Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L: ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011, 26:1616-1624.
• [22]Akobeng AK: Communicating the benefits and harms of treatments. Arch Dis Child 2008, 93:710-713.
• [23]Humaidan P, Bungum M, Bungum L, Yding Andersen C: Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004, 8:635-643.
• [24]Nyboe Andersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsboll S, Rasmussen PE, Lindenberg S, Bredkjaer HE, Meinertz H: Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod 2008, 23:427-434.
• [25]Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E: Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004, 8:175-182.
• [26]Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A: Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011, 95:1031-1036.
• [27]Motta E, Massaguer A, Serafini P, Beltrame A, Yadid I, Coslowsky M: Supplementation with rec-FSH or rec-LH is equally effective to modulate sub-optimal response for IVF cycles. A prospective randomized trial. Hum Reprod 2005, 20(Suppl 1):i125.
• [28]Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC: How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009, 91:749-766.
• [29]Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC: Evidence-based management of poor ovarian response. Ann N Y Acad Sci 2010, 1205:199-206.
• [30]Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G: Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009, 15:613-622.
• [31]Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, Ranieri A, D’Uva M, De Placido G: Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009, 18:9-14.
• [32]Kailasam C, Keay SD, Wilson P, Ford WC, Jenkins JM: Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Hum Reprod 2004, 19:1544-1547.
• [33]Keay SD, Liversedge NH, Mathur RS, Jenkins JM: Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997, 104:521-527.
• [34]van Wely M, Westergaard LG, Bossuyt PM, van der Veen F: Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003, 80:1086-1093.
• [35]Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, Whitcomb BW: The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012, 97:1108-1114.
• [36]Meniru GI, Craft IL: Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment. Hum Reprod 1997, 12:2129-2132.
• [37]Timeva T, Milachich T, Antonova I, Arabaji T, Shterev A, Omar HA: Correlation between number of retrieved oocytes and pregnancy rate after in vitro fertilization/intracytoplasmic sperm infection. ScientificWorldJournal 2006, 6:686-690.
• [38]Lane DE, Vittinghoff E, Croughan MS, Cedars MI, Fujimoto VY: Gonadotropin stimulation demonstrates a ceiling effect on in vitro fertilization outcomes. Fertil Steril 2006, 85:1708-1713.
• [39]Yih MC, Spandorfer SD, Rosenwaks Z: Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories. Fertil Steril 2005, 83:24-29.
• [40]Stern JE, Goldman MB, Hatasaka H, MacKenzie TA, Surrey ES, Racowsky C: Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study. Fertil Steril 2009, 91:767-776.
• [41]Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A: Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011, 26:1768-1774.
• [42]Stoop D, Ermini B, Polyzos NP, Haentjens P, De Vos M, Verheyen G, Devroey P: Reproductive potential of a metaphase II oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles. Hum Reprod 2012, 27:2030-2035.
• [43]Lukaszuk K, Kunicki M, Liss J, Lukaszuk M, Jakiel G: Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2013, 168:173-177.
• [44]Bosch E, Ezcurra D: Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol 2011, 9:82. BioMed Central Full Text
• [45]Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL: The poor responder in IVF: is the prognosis always poor?: a systematic review. Hum Reprod Update 2012, 18:1-11.
• [46]Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170.
• [47]Williams RS: The Serono r-hFSH and r-hLH Study Group: A multi-center study comparing the efficacy of recombinant human follicle stimulating hormone (r-hFSH, Gonal-Ft) versus r-hFSH plus recombinant human luteinizing hormone (r-hLH, Lhadit) in patients undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART). Fertil Steril 2000, 74(suppl 1):S228-S229.
• [48]Merck Serono: MS8839: A phase IIIb, open, randomized, parallel group, multicentre study to compare the safety and efficacy of recombinant human follicle stimulating hormone (Gonal-F) alone with r-hFSH plus recombinant human luteinizing hormone (Lhadi) for superovulation in women undergoing in vitro fertilization and embryo transfer. Geneva: Data on file; 2000.
• [49]Merck Serono: MS9032: A comparative clinical trial on treatment with r-hFSH alone or supplemented with r-hLH for induction of superovulation in IVF/ET. Geneva: Data on file; 2001.
• [50]Merck Serono: MS9029: Multicentric, randomized, controlled clinical trial to assess the efficacy and safety of the supplementation of r-hLH to r-hFSH treatments for controlled ovarian stimulation in patients with poor response in previous IVF/ET cycles. Geneva: Data on file; 2001.
• [51]Balasch J, Creus M, Fabregues F, Civico S, Carmona F, Puerto B, Casamitjana R, Vanrell JA: The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J Assist Reprod Genet 2001, 18:250-256.
• [52]Merck Serono: MS9640: A phase III, single centre, parallel, randomised open label comparative study to assess the safety and efficacy of recombinant human luteinising hormone (Luveris) used in conjunction with recombinant human follicle stimulation hormone (GONAL-F) in women undergoing multifollicular development for assisted reproduction. Geneva: Data on file; 2001.
• [53]Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A: Better implantation rate overimposing recombinant LH (Luveris) on recombinant FSH (Gonal F) in multiple follicular stimulation for IVF. Hum Reprod 2002, 17(suppl 1):134.
• [54]Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A: Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002, 5:104-108.
• [55]De Moustier B, Brinsden P, Bungum L, Fisch B, Pinkstone S, Warne D, Loumaye E: The effects of combined treatment of recombinant (r) FSH and rLH in ratios: 1:1, 2:1, and 3:1 in women aged 38–42 years undergoing IVF-ICSI treatment. Hum Reprod 2002, 17(Suppl 1):55.
• [56]Ludwig M, Katalinic A, Schultze-Mosgau A, Griesinger G, Schroeder AK, Diedrich K: LH supplementation in GnRH antagonist protocols: preliminary results of a prospective, randomized study. Hum Reprod 2003, 18(suppl 1):×viii3.
• [57]Sauer MV, Thornton MH, Schoolcraft W, Frishman GN: Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 2004, 9:487-493.
• [58]Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, Jayot S, Hugues JN: Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004, 19:1979-1984.
• [59]Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R: Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 2005, 20:1200-1206.
• [60]Demirol A, Gurgan T, Girgin B: Supplementation of rec-LH for poor responder patients in ART. Hum Reprod 2005, 20(Suppl 1):i74.
• [61]De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, Ranieri A, Colacurci N, Mollo A: Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005, 20:390-396.
• [62]Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, Shoham Z: The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006, 21:90-94.
• [63]Ramirez M, Monzo A, Garcia-Gimeno T, Rubio J, Montanana V, Duque C, Herrero G, Romeu A: Role of LH administration during the follicullar phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF. Rev Iberoamer de Fertil 2006, 23:281-290.
• [64]Levi-Setti PE, Cavagna M, Bulletti C: Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol 2006, 126:212-216.
• [65]Abdelmassih V, Salgueiro L, Abdelmassih R, Carizza C: Less miscarriage rate using LH (rLH) in GnRH agonist long protocol. Hum Reprod 2006, 21(Suppl 1):i7.
• [66]Aytac R, Ozmen B, Satiroglu H, Aydos K, Baltaci V: Addition of r-LH to ovulation scheme of patients with low serum estradiol levels on days 5–6 improves ovulation induction outcomes. Hum Reprod 2006, 21(Suppl 1):i27.
• [67]Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J: Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006, 85:925-931.
• [68]Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC: Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007, 87:542-546.
• [69]Polidoropoulos N, Papanikopoulos C, Stefanis P, Tavaniotou M, Argyrou M, Doriza S, Sisi V, Karamalegos C, Moschopoulou M, Karagianni T, Christopikou D, Garantzioti A, Davies S, Mastrominas M: Addition of exogenous recombinant LH in poor responders protocols: does it really help? Hum Reprod 2007, 22(Suppl 1):i4.
• [70]Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K: Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril 2007, 88:665-669.
• [71]Barrenetxea G, Agirregoikoa JA, Jimenez MR, Lopez De Larruzea A, Ganzabal T, Carbonero K: Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008, 89:546-553.
• [72]Pezzuto A, Ferrari B, Coppola F, Nardelli GB: LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol 2010, 26:118-124.
• [73]Brunet C, Dechanet C, Reyftmann I, Hamamah S, Hedon B, Dechaud H: Impact of r-LH supplementation on the estradiol level during ovarian stimulation for IVF: a randomized prospective study. Fertil Steril 2009, 92(Suppl):S240.
• [74]Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E: Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril 2009, 91:1837-1841.
• [75]Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, Burgues S: Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009, 19:879-887.
• [76]Lahoud R, Ryan J, Costello M, Illingworth P: Recombinant LH supplementation in patients with a relative reduction in LH levels during IVF/ICSIi cycles: a prospective randomised controlled trial. Hum Reprod 2010, 25(suppl 1):i90.
• [77]Kovacs P, Kovats T, Kaali SG: Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertil Steril 2010, 93:475-479.
• [78]Wiser A, Hourvitz A, Yinon Y, Levron J, Dor J, Elizur S: Recombinant human luteinizing hormone supplementation may improve embryo quality in in vitro fertilization/intracytoplasmic sperm injection cycles with gonadotrophin-releasing hormone antagonist protocol. Open J Obstet Gynecol 2011, 1:31-35.
• [79]Musters AM, Van Wely M, Mastenbroek S, Kaaijk EM, Repping S, van der Veen F, Mochtar MH: The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Hum Reprod 2012, 27:244-250.
• [80]Caserta D, Lisi F, Marci R, Ciardo F, Fazi A, Lisi R, Moscarini M: Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation? Gynecol Endocrinol 2011, 27:862-866.